Summary: OncoHost’s CLIA-certified proteomics laboratory received CAP accreditation, emphasizing its commitment to delivering precision-focused diagnostics for improved cancer care.
Takeaways:
- Commitment to Excellence: CAP accreditation highlights OncoHost’s adherence to rigorous quality and safety standards in its Cary laboratory, ensuring reliable diagnostic results for precision oncology.
- Innovative PROphet Platform: OncoHost’s proprietary PROphet tool analyzes over 7,000 proteins from a single blood sample to guide personalized cancer treatment by predicting therapeutic benefit.
- Advancing Precision Medicine: This milestone reinforces OncoHost’s mission to empower healthcare providers with cutting-edge, data-driven tools that optimize patient outcomes and redefine standards in cancer care.
OncoHost, a technology company focused on precision medicine for improved patient outcomes, announced that its CLIA-certified, high-throughput proteomics laboratory in Cary, North Carolina, received accreditation from the College of American Pathologists (CAP).
Getting CAP Accreditation
This accreditation underscores OncoHost’s commitment to the highest standards of quality and safety in laboratory practices. Its Cary facility is among a select group of specialized proteomics labs focused on human host response analysis and one of the only industrial-level operations dedicated to this purpose.
“We are honored to achieve CAP accreditation, a testament to our commitment to delivering the highest quality diagnostics,” said Amir Gelman, PhD, Director of Laboratory Operations & Assay Development at OncoHost. “This recognition reflects our dedication to precision and stringent compliance, ensuring healthcare providers and patients can trust the results guiding critical decisions in their cancer care.”
OncoHost’s Proteomics Platform
Central to OncoHost’s approach is its proprietary PROphet platform, a plasma-based proteomic pattern recognition tool that combines systems biology, bioinformatics, and artificial intelligence to support clinical decision-making.
Requiring only a single pre-treatment blood sample, PROphet analyzes patterns across approximately 7,000 proteins to generate a PROphet score—a clinically validated metric that reflects a patient’s likelihood of clinical benefit. This insight allows for effective and personalized treatment decisions, supporting patient-specific plans based on the unique biology of each individual. By predicting the likelihood of benefit from therapies such as immunotherapy alone or in combination with chemotherapy, PROphet enables physicians to make informed choices, reduce unnecessary treatments, and optimize patient survival.
Further Reading
“This CAP accreditation is a pivotal milestone for OncoHost as we advance our mission to bring the highest standards of quality and innovation to precision oncology,” says Ofer Sharon, MD, CEO of OncoHost. “I am incredibly proud of our dedicated team, whose expertise and commitment to excellence made this achievement possible. Our next-generation lab and PROphet platform provide physicians with critical insights that drive more effective, personalized treatment decisions. We are dedicated to empowering healthcare providers with reliable, data-driven tools that improve their patient outcomes and set a new benchmark in cancer care.”
The CAP Laboratory Accreditation Program, through rigorous peer inspection and evaluation, is designed to enhance patient safety by advancing the quality of pathology and laboratory services. OncoHost’s Cary lab demonstrated full compliance with CAP’s standards across areas such as quality control, safety, personnel qualifications, equipment maintenance, and operational management.
Photo: OncoHost
